Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

£993,000 Challenge Funding Awarded to Develop Animal Research Alternatives and Refinements

Published: Wednesday, February 13, 2013
Last Updated: Wednesday, February 13, 2013
Bookmark and Share
CRACK IT seeks proof-of-concepts to replace, reduce and refine animal use across efficacy and safety testing.

The CRACK IT open-innovation platform has awarded £993,000 to 11 challenge finalists who have been given just six months to develop the most successful proof-of-concepts for five business and technology challenges in preclinical research.

The platform primarily contributes to funding replacement, reduction and refinement (3Rs) in the use of animals in research and testing and is the first to utilise a two-phase approach specifically for this purpose, which combines industry sponsors with research council funding.

A Phase 1 proof-of-concept stage has been introduced to the platform to enable the exploration of more high-risk, innovative technologies and improve the chances of a viable product at the end of the project.

A flagship initiative of the UK's National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), CRACK IT aims to develop new technologies to benefit the 3Rs from challenges put forward by industry and academic sponsors. A mixing pot of industry, academic institutions and small and medium-sized enterprises (SMEs), CRACK IT combines funding with in-kind support from the sponsors - such as equipment and data.

2012 CRACK IT Challenges are:

•    The development of a cell-based/invertebrate approach to reproductive and toxicity screening to reduce and replace current mammalian methods.
•    Deploying a system to supply and use human, rather than animal, dorsal root ganglia for testing potential analgesic drugs.
•    Development of an imaging technique for detecting the distribution of large biomolecules in rodents, which in addition to reducing the use of animals will enable efficacy and safety studies to be ended earlier.
•    To improve rodent welfare, building a non-invasive system for monitoring mice in their home cage environment during behavioural studies.

The first CRACK IT 'mini challenge' funds the development of an injection aid suitable for use in rabbit studies to avoid potential eye damage associated with intravitreal injection. A marketable product is expected in six months.

The new two-phased approach has seen a total of 21 entrants showcasing their solutions to sponsors for up to £100,000 Phase 1 funding each for proof-of-concept development. Finalists will later pitch these proof-of-concepts in a 'Dragon's Den' style interview in July 2013, after which the successful challenge winners will be chosen to go through to Phase 2. Phase 2 winners receive up to £1 million further funding and 3 years to complete product development. Unsuccessful finalists may be given the option to combine or share data with challenge winners.

Making the announcement ahead of the NC3R's Annual Science Review meeting in London, Dr Vicky Robinson, Chief Executive, NC3Rs, said:

"CRACK IT supports SMEs and universities to develop their own marketable technology solutions. It is a leading example to the international scientific community of how the UK is using the latest approaches to fund alternatives to animal models and developing novel solutions to improve welfare where they continue to be used. Evolving the competition with a Phase 1 proof-of-concept approach ensures that more applicants get the chance to develop their ideas while reducing risk to the NC3Rs."

Additional funding to the NC3Rs from the Technology Strategy Board's Small Business Research Initiative and the Medical Research Council has made the Phase 1 proof-of-concept stage possible. Collaborating with the TSB is allowing the Centre to award contracts to universities, spin-off companies and SMEs. The new investment builds on the £3.5 million already funded under the CRACK IT scheme.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

£1.5M Invested to Improve Animal Research
The funding has been awarded to develop advanced imaging technologies, to maximise their potential to reduce animal use in a diverse range of preclinical research applications.
Tuesday, April 29, 2014
Rising to the Latest Technology Challenges in Animal Research
£1.56 million for proof-of-concepts awarded through the NC3Rs’ CRACK IT Challenges competition.
Thursday, January 30, 2014
£4.8m Funding Awarded for Smart Approaches to Reduce Animal use in Science
NC3Rs grants will develop new testing methods, infrastructure and technologies.
Wednesday, July 31, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Non-Disease Proteins Kill Brain Cells
Scientists at the forefront of cutting-edge research into neurodegenerative diseases such as Alzheimer’s and Parkinson’s have shown that the mere presence of protein aggregates may be as important as their form and identity in inducing cell death in brain tissue.
Potential Treatment for Life-Threatening Viral Infections Revealed
The findings point to new therapies for Dengue, West Nile and Ebola.
Gut Microbes Signal to the Brain When They're Full
Don't have room for dessert? The bacteria in your gut may be telling you something.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
Cancer-Fighting Tomato Component Traced
The metabolic pathway associated with lycopene, the bioactive red pigment found in tomatoes, has been traced by researchers at the University of Illinois.
Batten Disease may Benefit from Gene Therapy
NIH-funded animal study suggests one-shot approach to injecting genes.
Shedding Light on “Dark” Cellular Receptors
UNC and UCSF labs create a new research tool to find homes for two orphan cell-surface receptors, a crucial step toward finding better therapeutics and causes of drug side effects.
Molecule Proves Key to Brain Repair After Stroke
Scientists found that a molecule known as growth and differentiation factor 10 (GDF10) plays a key role in repair mechanisms following stroke.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos